• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

    10/30/23 7:00:00 AM ET
    $GRPH
    $PEAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Real Estate Investment Trusts
    Real Estate
    Get the next $GRPH alert in real time by email

    Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023.

    THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS

    – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0%
    – Third quarter new and renewal lease executions totaled 2.3 million square feet:
    • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 million square foot renewal at Medical City Dallas
    • Lab new and renewal lease executions totaled 211,000 square feet, including leases at three trophy campuses:
    •

    101,000 square feet at 331 Oyster Point in South San Francisco, California

    •

    61,000 square feet at 75 Hayden in Lexington, Massachusetts

    •

    23,000 square foot development lease at Vantage in South San Francisco, California, bringing the project to 52% pre-leased

    – In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife, where Healthpeak owns a total of 39 acres
    – Net debt to Adjusted EBITDAre was 5.2x as of September 30, 2023
    – Updated full year 2023 diluted earnings guidance to a range of $0.53 – $0.55 per share; increased the midpoint of 2023 FFO as Adjusted guidance by $0.02 per share and increased Total Portfolio Same-Store Cash (Adjusted) NOI growth guidance by 75 basis points at the midpoint
    – On October 29, 2023, Healthpeak's Board of Directors declared a quarterly common stock cash dividend of $0.30 per share to be paid on November 20, 2023, to stockholders of record as of the close of business on November 7, 2023
    – Received the GRESB Green Star designation for the twelfth consecutive year and recognized for leading corporate governance and ESG disclosures by Governance Intelligence and IR Magazine

    THIRD QUARTER COMPARISON

     

    Three Months Ended

    September 30, 2023

     

    Three Months Ended

    September 30, 2022

    (in thousands, except per share amounts)

    Amount

     

    Per Share

     

    Amount

     

    Per Share

    Net income, diluted

    $

    64,048

     

    $

    0.12

     

    $

    355,721

     

    $

    0.65

    Nareit FFO, diluted

     

    252,566

     

     

     

    0.46

     

     

     

    227,426

     

     

     

    0.42

     

    FFO as Adjusted, diluted

     

    251,647

     

     

     

    0.45

     

     

     

    235,504

     

     

     

    0.43

     

    AFFO, diluted

     

    219,645

     

     

     

    0.40

     

     

     

    194,963

     

     

     

    0.36

     

    YEAR TO DATE COMPARISON

     

    Nine Months Ended

    September 30, 2023

     

    Nine Months Ended

    September 30, 2022

    (in thousands, except per share amounts)

    Amount

     

    Per Share

     

    Amount

     

    Per Share

    Net income, diluted

    $

    233,497

     

    $

    0.43

     

    $

    496,341

     

    $

    0.91

    Nareit FFO, diluted

     

    730,764

     

     

     

    1.32

     

     

     

    711,713

     

     

     

    1.30

     

    FFO as Adjusted, diluted

     

    735,067

     

     

     

    1.33

     

     

     

    711,515

     

     

     

    1.30

     

    AFFO, diluted

     

    652,839

     

     

     

    1.18

     

     

     

    595,883

     

     

     

    1.09

     

    Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "September 30, 2023 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.

    SAME-STORE ("SS") OPERATING SUMMARY

    The table below outlines the year-over-year three-month and year-to-date SS Cash (Adjusted) NOI growth.

    Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth

     

    Three Month

     

    Year-To-Date

     

    SS Growth %

    % of SS

     

    SS Growth %

    % of SS

    Lab

    3.3

    %

    47.6

    %

     

    4.3

    %

    47.3

    %

    Outpatient Medical

    3.4

    %

    41.1

    %

     

    3.2

    %

    41.5

    %

    CCRC

    32.1

    %

    11.3

    %

     

    20.0

    %

    11.2

    %

    Total Portfolio

    6.0

    %

    100.0

    %

     

    5.4

    %

    100.0

    %

    DEVELOPMENT UPDATES

    VANTAGE PHASE I

    In September 2023, Healthpeak signed an additional 23,000 square foot lease with a global pharmaceutical company at its Vantage Phase I development in South San Francisco, California, bringing the property to 52% pre-leased.

    Strategically located on Forbes Boulevard and at the doorstep of Genentech's headquarters, the purpose-built lab campus will feature state-of-the-art design, an amenity center, flexible and efficient floor plates, and building systems accommodating a broad range of lab uses.

    WEST CAMBRIDGE

    In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife. Healthpeak's vision for the neighborhood incorporates Alewife's historic heritage and its innovative future by creating an active public realm driven by world-class real estate including lab, R&D and multi-family residential. Healthpeak owns a total of 39 acres in Alewife.

    GRAPHITE BIO LEASE MODIFICATION

    In October 2023, Healthpeak modified an approximately 85,200 square foot lease with Graphite Bio (NASDAQ:GRPH) at the Nexus on Grand campus in South San Francisco, California. Under the terms of the modification, Graphite Bio's lease expiration date was accelerated to December 31, 2024 in exchange for total consideration of $58 million, consisting of:

    i.

    $37 million cash payment, which is inclusive of the prepayment of Graphite Bio's 2024 contractual rent, including operating expense reimbursements, and termination and related fees; and

    ii.

    $21 million credit for future rent and operating expense reimbursements from the in-place 32,000 square foot subtenant; the subtenant has approximately one year remaining on the sublease, at which point it will become a direct tenant of Healthpeak with a lease term of approximately six years

    The $58 million in total consideration is equivalent to approximately 5+ years of Graphite Bio's original contractual rental payments, including operating expense reimbursements, and provides ample time for Healthpeak to release the remaining 53,000 square feet of fully built-out, Class A space to new tenants. Healthpeak retains the right to immediately release this space with no change in the payments due from Graphite Bio or the subtenant.

    ESG

    Healthpeak received the GRESB Green Star designation for the twelfth consecutive year. Healthpeak was also named a finalist by Governance Intelligence and IR Magazine for Best Proxy Statement for the fourth consecutive year and Best ESG Reporting for the second consecutive year, and included in Fortune's list of Best Workplaces in Real Estate for the second consecutive year.

    To learn more about Healthpeak's commitment to responsible business and view our 2022 ESG Report, please visit www.healthpeak.com/ESG.

    DIVIDEND

    On October 29, 2023, Healthpeak's Board declared a quarterly common stock cash dividend of $0.30 per share to be paid on November 20, 2023, to stockholders of record as of the close of business on November 7, 2023.

    2023 GUIDANCE

    We are updating the following guidance ranges for full year 2023:

    • Diluted earnings per common share from $0.49 – $0.53 to $0.53 – $0.55
    • Diluted Nareit FFO per share from $1.72 – $1.76 to $1.76 – $1.78
    • Diluted FFO as Adjusted per share from $1.73 – $1.77 to $1.76 – $1.78
    • Total Portfolio Same-Store Cash (Adjusted) NOI growth from 3.25% – 4.75% to 4.25% – 5.25%

    These estimates do not reflect the potential impact from unannounced future transactions. These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2023. For additional details and assumptions underlying this guidance, please see page 38 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.

    UPDATED CONFERENCE CALL INFORMATION

    Healthpeak has scheduled a conference call and webcast for Monday, October 30, 2023, at 8:30 a.m. Eastern Time.

    The conference call can be accessed in the following ways:

    • Healthpeak's website: https://ir.healthpeak.com/news-events
    • Webcast: https://events.q4inc.com/attendee/248022751. Joining via webcast is recommended for those who will not be asking questions.
    • Telephone: The participant dial-in number is (888) 330-2513 or (240) 789-2726 (international). The conference ID number is 58822.

    An archive of the webcast will be available on Healthpeak's website through October 30, 2024, and a telephonic replay can be accessed through November 6, 2023, by dialing (800) 770-2030 or (647) 362-9199 (international) and entering conference ID number 58822.

    ABOUT HEALTHPEAK

    Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate for healthcare discovery and delivery.

    FORWARD-LOOKING STATEMENTS

    Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, capital recycling plans, financing activities, or other transactions discussed in this release; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2023 Guidance." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, labor costs, and unemployment; the ability of our existing and future tenants, operators, and borrowers to conduct their respective businesses in a manner that generates sufficient income to make rent and loan payments to us; the financial condition of our tenants, operators, and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement activity risks, including project abandonments, project delays, and lower profits than expected; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through RIDEA structures; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners' financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread; the loss or limited availability of our key personnel; our reliance on information technology systems and the potential impact of system failures, disruptions, or breaches; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, volatility or uncertainty in the capital markets, and other factors; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; bank failures or other events affecting financial institutions; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a REIT; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

    Healthpeak Properties, Inc.

    Consolidated Balance Sheets

    In thousands, except share and per share data

     

     

    September 30,

    2023

     

    December 31,

    2022

    Assets

     

     

     

    Real estate:

     

     

     

    Buildings and improvements

    $

    13,097,282

     

     

    $

    12,784,078

     

    Development costs and construction in progress

     

    863,341

     

     

     

    760,355

     

    Land and improvements

     

    2,657,602

     

     

     

    2,667,188

     

    Accumulated depreciation and amortization

     

    (3,498,077

    )

     

     

    (3,188,138

    )

    Net real estate

     

    13,120,148

     

     

     

    13,023,483

     

    Loans receivable, net of reserves of $8,023 and $8,280

     

    225,881

     

     

     

    374,832

     

    Investments in and advances to unconsolidated joint ventures

     

    745,381

     

     

     

    706,677

     

    Accounts receivable, net of allowance of $2,077 and $2,399

     

    59,085

     

     

     

    53,436

     

    Cash and cash equivalents

     

    63,478

     

     

     

    72,032

     

    Restricted cash

     

    50,449

     

     

     

    54,802

     

    Intangible assets, net

     

    339,191

     

     

     

    418,061

     

    Assets held for sale, net

     

    8,277

     

     

     

    49,866

     

    Right-of-use asset, net

     

    233,480

     

     

     

    237,318

     

    Other assets, net

     

    757,164

     

     

     

    780,722

     

    Total assets

    $

    15,602,534

     

     

    $

    15,771,229

     

     

     

     

     

    Liabilities and Equity

     

     

     

    Bank line of credit and commercial paper

    $

    424,000

     

     

    $

    995,606

     

    Term loans

     

    496,603

     

     

     

    495,957

     

    Senior unsecured notes

     

    5,401,461

     

     

     

    4,659,451

     

    Mortgage debt

     

    342,349

     

     

     

    346,599

     

    Intangible liabilities, net

     

    133,668

     

     

     

    156,193

     

    Liabilities related to assets held for sale, net

     

    39

     

     

     

    4,070

     

    Lease liability

     

    204,762

     

     

     

    208,515

     

    Accounts payable, accrued liabilities, and other liabilities

     

    687,650

     

     

     

    772,485

     

    Deferred revenue

     

    879,174

     

     

     

    844,076

     

    Total liabilities

     

    8,569,706

     

     

     

    8,482,952

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

    Redeemable noncontrolling interests

     

    49,016

     

     

     

    105,679

     

     

     

     

     

    Common stock, $1.00 par value: 750,000,000 shares authorized; 547,072,311 and 546,641,973 shares issued and outstanding

     

    547,072

     

     

     

    546,642

     

    Additional paid-in capital

     

    10,401,994

     

     

     

    10,349,614

     

    Cumulative dividends in excess of earnings

     

    (4,528,508

    )

     

     

    (4,269,689

    )

    Accumulated other comprehensive income (loss)

     

    36,747

     

     

     

    28,134

     

    Total stockholders' equity

     

    6,457,305

     

     

     

    6,654,701

     

     

     

     

     

    Joint venture partners

     

    313,402

     

     

     

    327,721

     

    Non-managing member unitholders

     

    213,105

     

     

     

    200,176

     

    Total noncontrolling interests

     

    526,507

     

     

     

    527,897

     

     

     

     

     

    Total equity

     

    6,983,812

     

     

     

    7,182,598

     

     

     

     

     

    Total liabilities and equity

    $

    15,602,534

     

     

    $

    15,771,229

     

     

    Healthpeak Properties, Inc.

    Consolidated Statements of Operations

    In thousands, except per share data

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Revenues:

     

     

     

     

     

    Rental and related revenues

    $

    417,075

     

     

    $

    392,301

     

     

    $

    1,219,473

     

     

    $

    1,149,530

     

    Resident fees and services

     

    133,808

     

     

     

    122,142

     

     

     

    391,076

     

     

     

    369,062

     

    Interest income

     

    5,360

     

     

     

    5,963

     

     

     

    16,802

     

     

     

    16,950

     

    Income from direct financing leases

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,168

     

    Total revenues

     

    556,243

     

     

     

    520,406

     

     

     

    1,627,351

     

     

     

    1,536,710

     

     

     

     

     

     

     

     

     

    Costs and expenses:

     

     

     

     

     

     

     

    Interest expense

     

    50,510

     

     

     

    44,078

     

     

     

    147,547

     

     

     

    123,531

     

    Depreciation and amortization

     

    184,559

     

     

     

    173,190

     

     

     

    561,357

     

     

     

    531,412

     

    Operating

     

    232,734

     

     

     

    220,208

     

     

     

    677,659

     

     

     

    642,499

     

    General and administrative

     

    23,093

     

     

     

    24,549

     

     

     

    73,576

     

     

     

    73,161

     

    Transaction costs

     

    36

     

     

     

    728

     

     

     

    3,098

     

     

     

    1,636

     

    Impairments and loan loss reserves (recoveries), net

     

    (550

    )

     

     

    3,407

     

     

     

    (156

    )

     

     

    3,678

     

    Total costs and expenses

     

    490,382

     

     

     

    466,160

     

     

     

    1,463,081

     

     

     

    1,375,917

     

    Other income (expense):

     

     

     

     

     

     

     

    Gain (loss) on sales of real estate, net

     

    —

     

     

     

    (4,149

    )

     

     

    86,463

     

     

     

    10,047

     

    Other income (expense), net

     

    1,481

     

     

     

    305,678

     

     

     

    4,208

     

     

     

    326,855

     

    Total other income (expense), net

     

    1,481

     

     

     

    301,529

     

     

     

    90,671

     

     

     

    336,902

     

     

     

     

     

     

     

     

     

    Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures

     

    67,342

     

     

     

    355,775

     

     

     

    254,941

     

     

     

    497,695

     

    Income tax benefit (expense)

     

    (787

    )

     

     

    3,834

     

     

     

    (2,225

    )

     

     

    3,775

     

    Equity income (loss) from unconsolidated joint ventures

     

    2,101

     

     

     

    (325

    )

     

     

    6,646

     

     

     

    2,141

     

    Income (loss) from continuing operations

     

    68,656

     

     

     

    359,284

     

     

     

    259,362

     

     

     

    503,611

     

     

     

     

     

     

     

     

     

    Income (loss) from discontinued operations

     

    —

     

     

     

    (1,298

    )

     

     

    —

     

     

     

    2,011

     

     

     

     

     

     

     

     

     

    Net income (loss)

     

    68,656

     

     

     

    357,986

     

     

     

    259,362

     

     

     

    505,622

     

    Noncontrolling interests' share in continuing operations

     

    (4,442

    )

     

     

    (4,016

    )

     

     

    (24,297

    )

     

     

    (11,701

    )

    Net income (loss) attributable to Healthpeak Properties, Inc.

     

    64,214

     

     

     

    353,970

     

     

     

    235,065

     

     

     

    493,921

     

    Participating securities' share in earnings

     

    (166

    )

     

     

    (604

    )

     

     

    (1,568

    )

     

     

    (2,523

    )

    Net income (loss) applicable to common shares

    $

    64,048

     

     

    $

    353,366

     

     

    $

    233,497

     

     

    $

    491,398

     

     

     

     

     

     

     

     

     

    Basic earnings (loss) per common share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.12

     

     

    $

    0.66

     

     

    $

    0.43

     

     

    $

    0.91

     

    Discontinued operations

     

    —

     

     

     

    0.00

     

     

     

    —

     

     

     

    0.00

     

    Net income (loss) applicable to common shares

    $

    0.12

     

     

    $

    0.66

     

     

    $

    0.43

     

     

    $

    0.91

     

     

     

     

     

     

     

     

     

    Diluted earnings (loss) per common share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.12

     

     

    $

    0.65

     

     

    $

    0.43

     

     

    $

    0.91

     

    Discontinued operations

     

    —

     

     

     

    0.00

     

     

     

    —

     

     

     

    0.00

     

    Net income (loss) applicable to common shares

    $

    0.12

     

     

    $

    0.65

     

     

    $

    0.43

     

     

    $

    0.91

     

     

     

     

     

     

     

     

     

    Weighted average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    547,062

     

     

     

    538,417

     

     

     

    546,978

     

     

     

    539,105

     

    Diluted

     

    547,331

     

     

     

    546,015

     

     

     

    547,247

     

     

     

    544,852

     

     

    Healthpeak Properties, Inc.

    Funds From Operations

    In thousands, except per share data

     

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Net income (loss) applicable to common shares

     

    $

    64,048

     

     

    $

    353,366

     

     

    $

    233,497

     

     

    $

    491,398

     

    Real estate related depreciation and amortization

     

     

    184,559

     

     

     

    173,190

     

     

     

    561,357

     

     

     

    531,412

     

    Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures

     

     

    6,190

     

     

     

    8,704

     

     

     

    18,076

     

     

     

    19,049

     

    Noncontrolling interests' share of real estate related depreciation and amortization

     

     

    (4,571

    )

     

     

    (4,464

    )

     

     

    (14,042

    )

     

     

    (14,487

    )

    Loss (gain) on sales of depreciable real estate, net

     

     

    —

     

     

     

    5,280

     

     

     

    (86,463

    )

     

     

    (11,408

    )

    Healthpeak's share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures

     

     

    —

     

     

     

    239

     

     

     

    —

     

     

     

    89

     

    Noncontrolling interests' share of gain (loss) on sales of depreciable real estate, net

     

     

    —

     

     

     

    —

     

     

     

    11,546

     

     

     

    12

     

    Loss (gain) upon change of control, net(1)

     

     

    —

     

     

     

    (311,438

    )

     

     

    (234

    )

     

     

    (311,438

    )

    Taxes associated with real estate dispositions

     

     

    —

     

     

     

    197

     

     

     

    —

     

     

     

    31

     

    Nareit FFO applicable to common shares

     

     

    250,226

     

     

     

    225,074

     

     

     

    723,737

     

     

     

    704,658

     

    Distributions on dilutive convertible units and other

     

     

    2,340

     

     

     

    2,352

     

     

     

    7,027

     

     

     

    7,055

     

    Diluted Nareit FFO applicable to common shares

     

    $

    252,566

     

     

    $

    227,426

     

     

    $

    730,764

     

     

    $

    711,713

     

    Diluted Nareit FFO per common share

     

    $

    0.46

     

     

    $

    0.42

     

     

    $

    1.32

     

     

    $

    1.30

     

    Weighted average shares outstanding - diluted Nareit FFO

     

     

    554,614

     

     

     

    546,015

     

     

     

    554,535

     

     

     

    546,677

     

    Impact of adjustments to Nareit FFO:

     

     

     

     

     

     

     

     

    Transaction-related items

     

    $

    49

     

     

    $

    681

     

     

    $

    2,993

     

     

    $

    1,573

     

    Other impairments (recoveries) and other losses (gains), net(2)

     

     

    (602

    )

     

     

    2,897

     

     

     

    557

     

     

     

    (5,874

    )

    Restructuring and severance-related charges

     

     

    —

     

     

     

    —

     

     

     

    1,368

     

     

     

    —

     

    Casualty-related charges (recoveries), net(3)

     

     

    (367

    )

     

     

    4,514

     

     

     

    (610

    )

     

     

    4,103

     

    Total adjustments

     

     

    (920

    )

     

     

    8,092

     

     

     

    4,308

     

     

     

    (198

    )

    FFO as Adjusted applicable to common shares

     

     

    249,306

     

     

     

    233,166

     

     

     

    728,045

     

     

     

    704,460

     

    Distributions on dilutive convertible units and other

     

     

    2,341

     

     

     

    2,338

     

     

     

    7,022

     

     

     

    7,055

     

    Diluted FFO as Adjusted applicable to common shares

     

    $

    251,647

     

     

    $

    235,504

     

     

    $

    735,067

     

     

    $

    711,515

     

    Diluted FFO as Adjusted per common share

     

    $

    0.45

     

     

    $

    0.43

     

     

    $

    1.33

     

     

    $

    1.30

     

    Weighted average shares outstanding - diluted FFO as Adjusted

     

     

    554,614

     

     

     

    546,015

     

     

     

    554,535

     

     

     

    546,677

     

     

    (1)

     

    The three and nine months ended September 30, 2022 include a gain upon change of control related to the sale of a 30% interest to a sovereign wealth fund and deconsolidation of seven previously consolidated lab buildings in South San Francisco, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.

    (2)

     

    The nine months ended September 30, 2022 includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) a $23 million gain on sale of a hospital under a direct financing lease and (ii) $14 million of expenses incurred for tenant relocation and other costs associated with the demolition of an outpatient medical building. The three and nine months ended September 30, 2023 and 2022 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.

    (3)

     

    Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.

    Healthpeak Properties, Inc.

    Adjusted Funds From Operations

    In thousands

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    FFO as Adjusted applicable to common shares

    $

    249,306

     

     

    $

    233,166

     

     

    $

    728,045

     

     

    $

    704,460

     

    Stock-based compensation amortization expense

     

    3,434

     

     

     

    4,614

     

     

     

    10,966

     

     

     

    14,635

     

    Amortization of deferred financing costs

     

    3,054

     

     

     

    2,691

     

     

     

    8,828

     

     

     

    8,069

     

    Straight-line rents(1)

     

    (7,279

    )

     

     

    (12,965

    )

     

     

    (12,710

    )

     

     

    (36,837

    )

    AFFO capital expenditures

     

    (24,031

    )

     

     

    (24,358

    )

     

     

    (66,264

    )

     

     

    (75,103

    )

    Deferred income taxes

     

    (430

    )

     

     

    (2,814

    )

     

     

    (933

    )

     

     

    (3,741

    )

    Amortization of above (below) market lease intangibles, net

     

    (5,626

    )

     

     

    (5,876

    )

     

     

    (20,267

    )

     

     

    (17,528

    )

    Other AFFO adjustments

     

    (1,123

    )

     

     

    (1,144

    )

     

     

    (1,852

    )

     

     

    (3,017

    )

    AFFO applicable to common shares

     

    217,305

     

     

     

    193,314

     

     

     

    645,813

     

     

     

    590,938

     

    Distributions on dilutive convertible units and other

     

    2,340

     

     

     

    1,649

     

     

     

    7,026

     

     

     

    4,945

     

    Diluted AFFO applicable to common shares

    $

    219,645

     

     

    $

    194,963

     

     

    $

    652,839

     

     

    $

    595,883

     

    Diluted AFFO per common share

    $

    0.40

     

     

    $

    0.36

     

     

    $

    1.18

     

     

    $

    1.09

     

    Weighted average shares outstanding - diluted AFFO

     

    554,614

     

     

     

    544,190

     

     

     

    554,535

     

     

     

    544,852

     

     

    (1)

     

    The nine months ended September 30, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. This write-off is reflected as a reduction of rental and related revenues in the Consolidated Statements of Operations.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231030819874/en/

    Get the next $GRPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRPH
    $PEAK

    CompanyDatePrice TargetRatingAnalyst
    Healthpeak Properties Inc.
    $PEAK
    2/12/2024$19.00Underperform → Neutral
    Exane BNP Paribas
    Healthpeak Properties Inc.
    $PEAK
    1/30/2024$21.00Hold
    Deutsche Bank
    Healthpeak Properties Inc.
    $PEAK
    1/12/2024$20.00 → $23.00Sector Perform → Sector Outperform
    Scotiabank
    Healthpeak Properties Inc.
    $PEAK
    11/13/2023$17.50Neutral → Underperform
    BofA Securities
    Healthpeak Properties Inc.
    $PEAK
    10/11/2023$18.00Underperform
    Exane BNP Paribas
    Healthpeak Properties Inc.
    $PEAK
    10/3/2023$19.00Neutral
    Wedbush
    Healthpeak Properties Inc.
    $PEAK
    4/24/2023$29.00 → $25.00Neutral → Buy
    Mizuho
    Healthpeak Properties Inc.
    $PEAK
    4/20/2023$23.00Equal Weight
    Wells Fargo
    More analyst ratings

    $GRPH
    $PEAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

      SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      4/8/24 2:46:09 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Graphite Bio Inc.

      SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:30:24 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Graphite Bio Inc.

      SC 13D - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:16:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    $PEAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties to Present at the Citi 2024 Global Property CEO Conference and Publishes Updated Investor Presentation

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced today that Scott Brinker, its President and Chief Executive Officer, is scheduled to present at the Citi 2024 Global Property CEO Conference. The presentation is scheduled for 11:40 a.m. Eastern Time on Tuesday, March 5, 2024. You can access the webcast by visiting our website at https://ir.healthpeak.com/news-events/default.aspx. A replay will be available on our website through March 5, 2025. Additionally, Healthpeak has published an updated investor presentation in advance of upcoming investor meetings. The presentation is available on Heal

      3/1/24 8:45:00 AM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate
    • Healthpeak Properties Closes Merger with Physicians Realty Trust

      Healthpeak Properties, Inc. (NYSE:PEAK) ("Healthpeak") today announced that it has closed on the previously announced merger with Physicians Realty Trust. The combined company will operate under the name "Healthpeak Properties, Inc." and is expected to begin trading under the ticker symbol "DOC" at the open of trading on The New York Stock Exchange on March 4, 2024. "We are pleased to announce the completion of our merger with Physicians Realty Trust," said Scott Brinker, President and Chief Executive Officer of Healthpeak. "We believe this transaction augments our earnings, balance sheet, and platform. Our integration efforts are progressing ahead of schedule with property management int

      3/1/24 8:36:00 AM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    $PEAK
    Financials

    Live finance-specific insights

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Closes Merger with Physicians Realty Trust

      Healthpeak Properties, Inc. (NYSE:PEAK) ("Healthpeak") today announced that it has closed on the previously announced merger with Physicians Realty Trust. The combined company will operate under the name "Healthpeak Properties, Inc." and is expected to begin trading under the ticker symbol "DOC" at the open of trading on The New York Stock Exchange on March 4, 2024. "We are pleased to announce the completion of our merger with Physicians Realty Trust," said Scott Brinker, President and Chief Executive Officer of Healthpeak. "We believe this transaction augments our earnings, balance sheet, and platform. Our integration efforts are progressing ahead of schedule with property management int

      3/1/24 8:36:00 AM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate
    • Healthpeak Properties, Inc. and Healthpeak OP, LLC Complete Consent Solicitation and Offers to Guarantee and Receive Required Consents to Amend Physicians Realty L.P. Indentures

      Healthpeak Properties, Inc. (NYSE:PEAK) ("Healthpeak") today announced that, in connection with its and Healthpeak OP, LLC's ("Healthpeak OP") previously announced consent solicitation and offers to guarantee for Physicians Realty L.P. (a consolidated subsidiary of Physicians Realty Trust (NYSE: DOC) ("Physicians Realty Trust" or "DOC")) senior notes related to Healthpeak's agreement to merge with Physicians Realty Trust (the "Merger"), it has received the required consents from the holders of the outstanding Physicians Realty L.P. senior notes listed below (collectively, the "DOC Notes") to adopt the proposed amendments to each of the supplemental indentures to the Senior Indenture (each,

      2/26/24 4:15:00 PM ET
      $DOC
      $PEAK
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    $PEAK
    SEC Filings

    See more
    • SEC Form 424B3 filed by Graphite Bio Inc.

      424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/9/24 4:18:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Graphite Bio Inc.

      10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 5:11:18 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 4:05:56 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    $PEAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)

      3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/28/24 4:31:03 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    $PEAK
    Leadership Updates

    Live Leadership Updates

    See more
    • American Homes 4 Rent Set to Join S&P MidCap 400

      NEW YORK, Feb. 26, 2024 /PRNewswire/ -- American Homes 4 Rent (NYSE:AMH) will replace Physicians Realty Trust (NYSE:DOC) in the S&P MidCap 400 effective prior to the opening of trading on Friday, March 1. S&P 500 constituent Healthpeak Properties Inc. (NYSE:PEAK) is acquiring Physicians Realty Trust in a deal expected to be completed soon pending final conditions. Post-merger, Healthpeak Properties will have a symbol change from PEAK to DOC. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector March 1, 2024 S&P MidCap 400 Addition American Homes 4 Rent AMH Real E

      2/26/24 6:04:00 PM ET
      $AMH
      $DOC
      $PEAK
      $SPGI
      Real Estate Investment Trusts
      Real Estate
      Finance: Consumer Services
      Finance
    • Faraday Future Appoints Scott Graziano, Senior Legal Executive with Extensive U.S. Public Company Experience, as Global General Counsel

      Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, today announced the Company's Board of Directors has appointed Scott Graziano as Global General Counsel; he will be based at the Company's Gardena, California, main campus near Los Angeles, effective immediately. In his new role, Mr. Graziano will report to the CEO of FF, and will serve on the Company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925744903/en/Faraday Future Appoints Scott Graziano, Senior Legal Executive wi

      9/25/23 10:22:00 PM ET
      $FFIE
      $PEAK
      $WDC
      Auto Manufacturing
      Consumer Discretionary
      Real Estate Investment Trusts
      Real Estate
    • Healthpeak Properties Board Appoints Kathy Sandstrom as Chair

      DENVER, April 27, 2023 /PRNewswire/ -- Healthpeak Properties, Inc. (NYSE:PEAK) announced today that Kathy Sandstrom was appointed as independent Chair of the Board of Directors. Ms. Sandstrom succeeds Brian Cartwright, who will continue to serve on the Board as an independent director. "Regular rotation of board leadership promotes effective corporate governance and introduces fresh perspectives and energy to board processes," said Mr. Cartwright. "After five years as Chair, the time is right for that rotation. Kathy's experience and Board tenure make her ideally suited to take on the added responsibilities of Board Chair. I take great pride in the proactive positioning of the Company that o

      4/27/23 4:15:00 PM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    $PEAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Lewis Sara Grootwassink bought $300,780 worth of shares (18,000 units at $16.71) (SEC Form 4)

      4 - HEALTHPEAK PROPERTIES, INC. (0000765880) (Issuer)

      3/4/24 5:46:15 PM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    $PEAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Healthpeak upgraded by Exane BNP Paribas with a new price target

      Exane BNP Paribas upgraded Healthpeak from Underperform to Neutral and set a new price target of $19.00

      2/12/24 7:12:05 AM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate
    • Deutsche Bank initiated coverage on Healthpeak with a new price target

      Deutsche Bank initiated coverage of Healthpeak with a rating of Hold and set a new price target of $21.00

      1/30/24 7:36:41 AM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate
    • Healthpeak upgraded by Scotiabank with a new price target

      Scotiabank upgraded Healthpeak from Sector Perform to Sector Outperform and set a new price target of $23.00 from $20.00 previously

      1/12/24 8:11:49 AM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate